Literature DB >> 20674997

Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats.

Deguo Wang1, Fengxiang Zhang, Wenzhi Shen, Minglong Chen, Bing Yang, Yuzhen Zhang, Kejiang Cao.   

Abstract

BACKGROUND: Mesenchymal stem cell transplantation is a promising new therapy to improve cardiac function after myocardial infarction (MI). The electrophysiological consequences of MSC implantation has not been systematically studied.
METHODS: We investigated the electrophysiological and arrhythmogenic effects of mesenchymal stem cells (MSCs) therapy in experimental infarction model. Rats were subjected to MI operation by LAD ligation and randomly allocated to receive intramyocardially injection PBS (MI-PBS) or 5 × 10(5) EGFP labeled MSCs (MI-MSCs). Electrophysiological study, histological examination, and western blotting were performed 2 weeks after cell transplantation.
RESULTS: Programmed electrical stimulation (PES) showed a significant reduced inducible ventricular tachycardias (VTs), raised ventricular fibrillation threshold (VFT) and prolonged ventricular effective refractory period (VERP) in MSC-treated rats compared to PBS-treated animals. MSC implantation led to markedly longer action potential duration (APD) and shorter activation time (AT) in infarcted border zone (IBZ) of left ventricular epicardium compared with PBS-treated hearts. Histological study revealed that fibrotic area and collagen deposition in infarcted region were significantly lower in MI-MSC group than in MI-PBS group. Abnormal alterations of Connexin 43 including reduction and lateralization were significantly attenuated by MSC treatment.
CONCLUSIONS: This study provide strong evidence that MSC implantation ameliorates interstitial fibrosis and the remodeling of gap junction, attenuates focal heterogeneity of reporlarization and conduction and reduces vulnerability to VTs. The results suggest that MSC transplantation might emerge as a new preventive strategy against VAs besides improving cardiac performance in ischemic heart disease.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20674997     DOI: 10.1016/j.ijcard.2010.07.025

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  24 in total

Review 1.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

Review 2.  Gap junctions and chagas disease.

Authors:  Daniel Adesse; Regina Coeli Goldenberg; Fabio S Fortes; Dumitru A Iacobas; Sanda Iacobas; Antonio Carlos Campos de Carvalho; Maria de Narareth Meirelles; Huan Huang; Milena B Soares; Herbert B Tanowitz; Luciana Ribeiro Garzoni; David C Spray
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

3.  Improved conduction and increased cell retention in healed MI using mesenchymal stem cells suspended in alginate hydrogel.

Authors:  Nikhil C Panda; Sean T Zuckerman; Olurotimi O Mesubi; David S Rosenbaum; Marc S Penn; J Kevin Donahue; Eben Alsberg; Kenneth R Laurita
Journal:  J Interv Card Electrophysiol       Date:  2014-09-19       Impact factor: 1.900

Review 4.  Arrhythmogenic risks of stem cell replacement therapy for cardiovascular diseases.

Authors:  Kang Chen; Yuting Huang; Radhika Singh; Zack Z Wang
Journal:  J Cell Physiol       Date:  2020-01-29       Impact factor: 6.384

5.  Comparison of cardiac stem cells and mesenchymal stem cells transplantation on the cardiac electrophysiology in rats with myocardial infarction.

Authors:  Shao-Xin Zheng; Yin-Lun Weng; Chang-Qing Zhou; Zhu-Zhi Wen; Hui Huang; Wei Wu; Jing-Feng Wang; Tong Wang
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

6.  Non-inferiority of microencapsulated mesenchymal stem cells to free cells in cardiac repair after myocardial infarction: A rationale for using paracrine factor(s) instead of cells.

Authors:  Andrey A Karpov; Maxim V Puzanov; Dmitry Yu Ivkin; Marina V Krasnova; Nikita A Anikin; Pavel M Docshin; Olga M Moiseeva; Michael M Galagudza
Journal:  Int J Exp Pathol       Date:  2019-04-24       Impact factor: 1.925

7.  Experimental and Computational Insight Into Human Mesenchymal Stem Cell Paracrine Signaling and Heterocellular Coupling Effects on Cardiac Contractility and Arrhythmogenicity.

Authors:  Joshua Mayourian; Timothy J Cashman; Delaine K Ceholski; Bryce V Johnson; David Sachs; Deepak A Kaji; Susmita Sahoo; Joshua M Hare; Roger J Hajjar; Eric A Sobie; Kevin D Costa
Journal:  Circ Res       Date:  2017-06-22       Impact factor: 17.367

Review 8.  Administration of mesenchymal stem cells in diabetic kidney disease: mechanisms, signaling pathways, and preclinical evidence.

Authors:  Yuexin Zhu; Manyu Luo; Xue Bai; Yan Lou; Ping Nie; Shan Jiang; Jicui Li; Bing Li; Ping Luo
Journal:  Mol Cell Biochem       Date:  2022-04-25       Impact factor: 3.396

9.  Mesenchymal stem cells improve cardiac conduction by upregulation of connexin 43 through paracrine signaling.

Authors:  Shwetha Mureli; Christopher P Gans; Dan J Bare; David L Geenen; Nalin M Kumar; Kathrin Banach
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-15       Impact factor: 4.733

10.  Growth factor-induced mobilization of cardiac progenitor cells reduces the risk of arrhythmias, in a rat model of chronic myocardial infarction.

Authors:  Leonardo Bocchi; Monia Savi; Gallia Graiani; Stefano Rossi; Aldo Agnetti; Francesca Stillitano; Costanza Lagrasta; Silvana Baruffi; Roberta Berni; Caterina Frati; Mario Vassalle; Umberto Squarcia; Elisabetta Cerbai; Emilio Macchi; Donatella Stilli; Federico Quaini; Ezio Musso
Journal:  PLoS One       Date:  2011-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.